AD 01 是一种 24 个氨基酸的 FKBPL(FK506 结合蛋白样)肽,具有有效的抗血管生成活性。 AD 01 与 CD44 受体结合并以 CD44 依赖性方式抑制肿瘤细胞迁移。
此产品仅用于科学研究,我们不为任何个人用途提供产品和服务
FKBPL (FK506-binding protein like)-based peptide. Binds to and upregulates expression of CD44. Inhibits breast cancer stem cell (BCSC) growth. Decreases pluripotency markers and promotes differentiation of BCSCs. Also inhibits endothelial cell migration as well as tubule and microvessel formation in vitro and in vivo. Blocks tumor growth in xenograft models.
Yakkundi et al (2013) The anti-migratory effects of FKBPL and its peptide derivative, AD-01: regulation of CD44 and the cytoskeletal pathway. PLoS One. 8 e55075 PMID:23457460 |McClements et al (2013) Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway. Clin.Cancer Res. 19 3881 PMID:23741069 |Valentine et al (2011) FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism. Clin.Cancer Res 17 1044 PMID:21364036
没有评价数据